CpG ODN对疫苗的增效作用及对病毒致病性和肿瘤生长的影响
|
摘要
含非甲基化CpG基序的寡聚脱氧核苷酸(CpG ODN)是Toll样受体9(TLR9)的激动剂,能刺激人及哺乳动物的天然免疫应答,在作为疫苗佐剂、抗病毒及抗肿瘤方面显示出应用前景。在本工作中,我们研究了CpG ODN对疫苗的增效作用及对病毒致病性和肿瘤生长的影响。
在筛选新型CpG ODN佐剂的实验中,证明本室自行设计的CpG ODN(BW006)能促进狂犬疫苗刺激狂犬病毒中和抗体更早、更高的产生,减少狂犬疫苗注射次数;此外,BW006能显著减低流感疫苗用量,增强流感疫苗诱导交叉免疫应答的效力。上述结果提示BW006可能成为一种高效的病毒疫苗佐剂。采用流感病毒感染小鼠模型,意外发现CpG ODN 1826可明显加重接种流感病毒小鼠的肺部感染,加速小鼠的死亡。这提示我们在病毒急性感染期间应当慎重使用免疫增强剂。在研究CpG ODN对肿瘤细胞是否存在直接影响的过程中,发现本室自行设计的CpG ODN(BW001)在体外抑制肿瘤细胞的粘附,在小鼠体内抑制肿瘤的生长及转移。这提示BW001可能成为通过抑制肿瘤细胞粘附发挥抗肿瘤作用的一种新型制剂。
Both viral infections and carcinoma are highly fatal diseases. Nearly seventy-five percent of infectious diseases are caused by virus. Hepatitis B virus, hepatitis C virus or human immunodeficiency virus can induce chronic infection with an increased risk of malignant cell transformation. Influenza virus and avian influenza virus easily emerge mutation or re-assortment and cause sustained pandemic. Furthermore, viral infections are associated with an increased risk of malignancy, autoallergic disease and allergy. Carcinoma is the second death reason in western countries and has become the first death reason in China according to the data from China's Ministry of Health in 2006. The incidences of lung cancer and breast cancer are the fastest increasing all over the world and displays increasing trend in young attributed to the effect of smoking and stress. CpG containing synthetic oligodeoxynucleotides (CpG ODN) can directly or indirectly activate immune system by recognizing toll like receptor 9 expressed major in B cells and plasmacytoid dendritic cells (pDC), induce the secretion of Th1-like cytokines, such as IFN, TNF-α、IL-6、IL-12、IL-18、IP-10, indicating that CpG ODN has the huge potential for anti-infective or anti-neoplastic applications.
To develop highly effective adjuvant for viral vaccines, investigate the influences of CpG ODN on the influenza infection and tumor growth, we finished the following three part experiments:
1 CpG ODN as adjuvant for virus vaccines
Viral infectious diseases are the most common contagious diseases and up to now there is no effective medical treatment for them. So, vaccine inoculation for prophylaxis of these kinds of diseases becomes extremly important. However, new types of vaccines, adjuvants or delivery systems are needed be developed for the following purposes: to improve the vaccine immunogenicity so that the vaccine could stimulate the earlier and higher antibody production, to enhance the vaccine ability of inducing Th2 response and to reduce the vaccine dose. To develop new type CpG ODN as virus vaccine adjuvant, we conducted the following experiments:
1.1 Activation of human PBMCs and mouse splenocytes stimulated by optimized CpG ODN
According to their structures and their activities in stimulating human peripheral blood mononuclear cells (hPBMCs) in vitro, CpG ODNs can be grouped into A-(also known as“type K”), B-(also known as“type K”) or C-types. Structurally, the A type CpG ODN has phosphodiester-backbone (PO) palindrome sequence containing CpG motif and phosphorothioate (PS)–modified polyG at the 3′and 5′ends. The A type CpG ODN can directly stimulate high level production of IFNα/βand secondarily activate natural killer (NK) cells. Structurally, the B type CpG ODN has full PS-modified backbone containing one or more CpG motif(s), and has no polyG structure. The B type CpG ODN strongly induces B cell proliferation and pDC maturation, and also activates NK cells indirectly. The structure of C type CpG ODN is similar to that of the A type CpG ODN except its full phosphorothioate-modified backbone. The C type CpG ODN has immune properties intermediate between the A and B types, inducing both B cell activation and IFNαsecretion. All types of CpG ODN have adjuvant properties. However, because of degrading rapidly by nuclease digestion in vivo, the instability of PO backbone is a restriction on the clinical application of the A type CpG ODN. The stimulation of B cell proliferation and secretion of large amounts of Ig, IL-6 and IL-10 induced by the B type CpG ODN is stronger than that did by the C type CpG ODN, which may be a partial reason for the focus studies on B type CpG ODN as adjuvant. Furthermore, the recognition of CpG motifs is different in variant species: the optimal CpG motif is GACGTT for stimulating the proliferation of mouse splenocytes but GTCGTT for stimulating the proliferation of hPMBCs. Based on these knowledges, we designed a large scale of CpG ODNs and used the 3H-TdR incorporation assay for the screening of the B type CpG ODN. A CpG ODN, designated as BW006, outshined with stronger ability to stimulate the proliferation of both hPBMCs and mouse splenocytes. Furthermore, B cell activation induced by BW006 was detected on a FACSCalibur. The result showed that BW006 could significantly up-regulate CD69 expression on CD19+ cells in human PBMCs and mouse splenocytes. These data indicate that BW006 may be developed into a potential adjuvant for human use and its potential can be primarily evaluated in mice before human clinical trial since BW006 is able to stimulate both human and mouse immune cells especially B cells.
1.2 Immunogenicity of inactivated rabies vaccine enhanced by BW006
Up to now, the postexposure prophylaxis (PEP) with vaccine is still a mainstream treatment for the people attacked by rabies virus infected animals. Obviously, it is required to develop rabies vaccines that induce an earlier and higher level production of rabies virus neutralizing antibody (RVNAb). Traditionally, rabies vaccine is administered in five intramuscular shots on day 0, 3, 7, 14, and 28. Overall, it is required to find an optimal adjuvant that not only promotes the rabies vaccines to induce an earlier and stronger RVNAb response, but also reduces their immunization shots. To determine the enhancement of BW006 on inactivated rabies vaccine (IRV), we performed a series experiments in mice. The result showed that: BW006 enhanced IRV to induce an earlier and much higher production of RVNAb, and aluminum delayed the RVNAb production; BW006 co-operated with aluminum to enhance the immunogenicity of IRV; BW006 reduced the immunization shots of rabies vaccines; BW006 augmented the rabies vaccine with or without aluminum to induce effective protection of mice against rabies virus. The results indicate that BW006 has the potential as rabies vaccine adjuvant. The immunization strategy against rabies might be adjusted to one in which the first shot is administered with rabies vaccine plus BW006, and the later shots with rabies vaccine containing both aluminum and BW006.
1.3 Immunogenicity of inactivated influenza vaccine enhanced by BW006
Influenza virus easily causes sustained pandemic and vaccine supply is insufficient to meed the needs of potential pandemic mediated by the frequent re-assortment between two different virus strains or subtype strains. To determine the enhancement of BW006 on inactivated influenza vaccine, we performed a series of experiments in mice. The results showed that: BW006 improved earlier production of high level antibody induced by low dose of H3N2 antigen and prolonged production of high level antibody induced by high dose of H3N2 antigen; BW006 reduced H3N2 antigen doses to 1/8th dose and enhanced recalled proliferation of mouse splenocytes of mice immunized with H3N2 antigen stimulated by different influenza subtype strain. Furthermore, we identified the enhancement effect of BW006 on the inactivated influenza spilit vaccine. Similarly, BW006 reduced the full vaccine dose to 1/10th dose and promoted IgG2a production in mouse serum. In conclusion, the superiority of BW006 as influenza vaccine adjuvant is to reduce vaccine dose, increase cross-reactivity to different subtype strain and induce Th1 response.
2 The influence of CpG ODN on the pathogenecity of influenza virus
Based on the production of large amounts of anti-infective materials by CpG ODN stimulated immune cells, we conducted the in vivo experiments to observe the influence of CpG ODN on the acute infection caused by influenza virus. Influenza virus FM1 stain, which is safety for human, was used to infect mice. Body weight, survival rate, lung pathology, the levels of XOD and IL-12 in BALF were used to evaluate the immune effect of CpG ODN 1826 (1826), a prototype of B type CpG ODN in mouse. We unexpectedly found that 1826 inoculated before the influenza virus attack provided no protection for infected mice. On the contrary, 1826 aggravated the interstitial pneumonia, accelerated the body weight loss and promoted the death of infected mice, accompanished with the improved activity of xanthine oxidase and the high level IL-12 production in bronchoalveolar lavage fluid. The results suggest that CpG ODN seems to have side effects on self-limited flu-like acute infection, and the possible reason may be due to the synergy of CpG ODN and virus to stimulate the over secretion of inflammatory cytokines which damage body itself. Consequently, immunostimulating agents such as CpG ODN should be used cautiously in patients suffering from acute viral infection because of their potential to augment viral pathogenecity.
3 The influence of CpG ODN on tumor growth
The complex pathogenesis of carcinoma is associated with the low cure rates and high recurrence rates of these kinds of diseases. Any single-target drugs are insufficient for the cancer therapy. Adherence properties of tumor cells have important effects on tumor growth, invasion, and metastasis, so inhibition of tumor adherence becomes a new way to cure cancer. To study the capability of CpG ODN on the inhibition of tumor adherence, B16 cells were selected as tumor cell models for in vitro and in vivo experiments.
3.1 The influence of CpG ODN on the tumor cell adherence in vitro
For the purpose of screening CpG ODN with the ability to inhibit tumor cell adherence, cell counting experiments were used. In the process, self-designed CpG ODN, named as BW001, outshined others because of its dose-dependent inhibitions of tumor cell adherence, spreading and growth in vitro. Furthermore, a panel of CpG ODN were synthesized based on the structure of BW001 and were tested for their capacity to inhibit tumor cell adherence. The result showed that more than 5 continuous guanines (G) and fully PS-modified backbone, but not CpG motif were the necessary structures for BW001’s activity to inhibit cell adherence. Moreover, the activity of BW001 could be blocked by polycations (including poly-L-lysine, poly-L-arginine and poly-L-ornithine) and affected by FITC labeling, and could not influenced by dextran sulfate and chlorochine. These results indicate that the activity of BW001 on the inhibition of tumor cell adherence displays specific structure-dependence and is associated with polyanion character, but has no relationships with scavenger receptor or TLR9. The reduced inhibiton of FITC-BW001 may be due to the effect of FITC molecular on the formation of BW001 polymers.
3.2 The influence of CpG ODN on the tumor cell adherence ex vivo
Tumor metastasis is a multistep process and dependeds in part on the interactions of tumor cells and extracellular matrix (ECM) or endothelial cells. To study the activity of BW001 on the inhibition of tumor metastasis, fibronetin and typeⅠcollagen were used to mimic ECM and human umbilical vein endothelial cells (HUVECs) were used to mimic angiogenesis. The results showed that BW001 could inhibit the tumor cell adherence on ECM or inhibit the conformation of ECM mimicked by fibronetin and typeⅠcollagen; BW001 could inhibit tumor cell adherence to HUVECs. The results indicate that BW001 may inhibit tumor metastasis through the inhibition of cell adherence on ECM or endothelial cells.
Adherence to endothelium of distant organs may be partially responsible for the preferential metastatic patterns associated with differetent tumor types. Melanoma cells typically form tumor metastasis primarily in the lung. To observe the influence of BW001 on the lung metastasis of B16 cells, fresh cryostat sections of lung tissue were used to mimic lung microenviroment. The results showed that BW001 could inhibit the B16 cell adherence on lung tissue, incidating that BW001 may reduce the metastasis of tumor by the inhibition of tumor cell adherence on distant organs.
3.3 The influence of BW001 on the tumorigenicity of B16 cell in mice
To study the effect of BW001 on the inhibition of tumor growth and metastasis in vivo, we established three kinds of tumor models in mice with intraperitoneal, subcutaneous or intravenous injection of B16 cells mixed with or without BW001. We found that the BW001 could significantly decrease the tumor colony formations in peritoneal cavity and prolong the survival of tumor-bearing mice, delay the growth of subcutaneous tumor and inhibit the lung disseminateion of B16 cells via tail vein injection. The activity of BW001 displays sequence-dependence and structure-dependence: CG reversed control for BW001 failed to prolong the survival of tumor-bearing mice as compared with solvent did, indicating sequence-specific is a necessary condition for BW001’s activity. Moreover, the suppressing effect was weakened when polyG tail was removed or fully PS-modified backbone was changed to partially PS-modified backbone. Further study showed that the tumor inhibition activity of BW001 in these tumor models was induced by the direct interaction of BW001 and B16 cells and potential activation of immune system stimulated by BW001 may also participate in anti-tumor effects in peritoneal tumor model.
Based on all these results, we conclude that:
1 self-designed CpG ODN (BW006) may be a potential adjuvant for rabies vaccine and influenz vaccine.
2 Because of their potential to augment viral pathogenecity, immunostimulating agents such as CpG ODN should be used cautiously in patients suffering from acute viral infection.
3 Self-designed CpG ODN (BW001) may be developed into novel anti-neoplastic medication with the ability of tumor cell inhibition.
在筛选新型CpG ODN佐剂的实验中,证明本室自行设计的CpG ODN(BW006)能促进狂犬疫苗刺激狂犬病毒中和抗体更早、更高的产生,减少狂犬疫苗注射次数;此外,BW006能显著减低流感疫苗用量,增强流感疫苗诱导交叉免疫应答的效力。上述结果提示BW006可能成为一种高效的病毒疫苗佐剂。采用流感病毒感染小鼠模型,意外发现CpG ODN 1826可明显加重接种流感病毒小鼠的肺部感染,加速小鼠的死亡。这提示我们在病毒急性感染期间应当慎重使用免疫增强剂。在研究CpG ODN对肿瘤细胞是否存在直接影响的过程中,发现本室自行设计的CpG ODN(BW001)在体外抑制肿瘤细胞的粘附,在小鼠体内抑制肿瘤的生长及转移。这提示BW001可能成为通过抑制肿瘤细胞粘附发挥抗肿瘤作用的一种新型制剂。
Both viral infections and carcinoma are highly fatal diseases. Nearly seventy-five percent of infectious diseases are caused by virus. Hepatitis B virus, hepatitis C virus or human immunodeficiency virus can induce chronic infection with an increased risk of malignant cell transformation. Influenza virus and avian influenza virus easily emerge mutation or re-assortment and cause sustained pandemic. Furthermore, viral infections are associated with an increased risk of malignancy, autoallergic disease and allergy. Carcinoma is the second death reason in western countries and has become the first death reason in China according to the data from China's Ministry of Health in 2006. The incidences of lung cancer and breast cancer are the fastest increasing all over the world and displays increasing trend in young attributed to the effect of smoking and stress. CpG containing synthetic oligodeoxynucleotides (CpG ODN) can directly or indirectly activate immune system by recognizing toll like receptor 9 expressed major in B cells and plasmacytoid dendritic cells (pDC), induce the secretion of Th1-like cytokines, such as IFN, TNF-α、IL-6、IL-12、IL-18、IP-10, indicating that CpG ODN has the huge potential for anti-infective or anti-neoplastic applications.
To develop highly effective adjuvant for viral vaccines, investigate the influences of CpG ODN on the influenza infection and tumor growth, we finished the following three part experiments:
1 CpG ODN as adjuvant for virus vaccines
Viral infectious diseases are the most common contagious diseases and up to now there is no effective medical treatment for them. So, vaccine inoculation for prophylaxis of these kinds of diseases becomes extremly important. However, new types of vaccines, adjuvants or delivery systems are needed be developed for the following purposes: to improve the vaccine immunogenicity so that the vaccine could stimulate the earlier and higher antibody production, to enhance the vaccine ability of inducing Th2 response and to reduce the vaccine dose. To develop new type CpG ODN as virus vaccine adjuvant, we conducted the following experiments:
1.1 Activation of human PBMCs and mouse splenocytes stimulated by optimized CpG ODN
According to their structures and their activities in stimulating human peripheral blood mononuclear cells (hPBMCs) in vitro, CpG ODNs can be grouped into A-(also known as“type K”), B-(also known as“type K”) or C-types. Structurally, the A type CpG ODN has phosphodiester-backbone (PO) palindrome sequence containing CpG motif and phosphorothioate (PS)–modified polyG at the 3′and 5′ends. The A type CpG ODN can directly stimulate high level production of IFNα/βand secondarily activate natural killer (NK) cells. Structurally, the B type CpG ODN has full PS-modified backbone containing one or more CpG motif(s), and has no polyG structure. The B type CpG ODN strongly induces B cell proliferation and pDC maturation, and also activates NK cells indirectly. The structure of C type CpG ODN is similar to that of the A type CpG ODN except its full phosphorothioate-modified backbone. The C type CpG ODN has immune properties intermediate between the A and B types, inducing both B cell activation and IFNαsecretion. All types of CpG ODN have adjuvant properties. However, because of degrading rapidly by nuclease digestion in vivo, the instability of PO backbone is a restriction on the clinical application of the A type CpG ODN. The stimulation of B cell proliferation and secretion of large amounts of Ig, IL-6 and IL-10 induced by the B type CpG ODN is stronger than that did by the C type CpG ODN, which may be a partial reason for the focus studies on B type CpG ODN as adjuvant. Furthermore, the recognition of CpG motifs is different in variant species: the optimal CpG motif is GACGTT for stimulating the proliferation of mouse splenocytes but GTCGTT for stimulating the proliferation of hPMBCs. Based on these knowledges, we designed a large scale of CpG ODNs and used the 3H-TdR incorporation assay for the screening of the B type CpG ODN. A CpG ODN, designated as BW006, outshined with stronger ability to stimulate the proliferation of both hPBMCs and mouse splenocytes. Furthermore, B cell activation induced by BW006 was detected on a FACSCalibur. The result showed that BW006 could significantly up-regulate CD69 expression on CD19+ cells in human PBMCs and mouse splenocytes. These data indicate that BW006 may be developed into a potential adjuvant for human use and its potential can be primarily evaluated in mice before human clinical trial since BW006 is able to stimulate both human and mouse immune cells especially B cells.
1.2 Immunogenicity of inactivated rabies vaccine enhanced by BW006
Up to now, the postexposure prophylaxis (PEP) with vaccine is still a mainstream treatment for the people attacked by rabies virus infected animals. Obviously, it is required to develop rabies vaccines that induce an earlier and higher level production of rabies virus neutralizing antibody (RVNAb). Traditionally, rabies vaccine is administered in five intramuscular shots on day 0, 3, 7, 14, and 28. Overall, it is required to find an optimal adjuvant that not only promotes the rabies vaccines to induce an earlier and stronger RVNAb response, but also reduces their immunization shots. To determine the enhancement of BW006 on inactivated rabies vaccine (IRV), we performed a series experiments in mice. The result showed that: BW006 enhanced IRV to induce an earlier and much higher production of RVNAb, and aluminum delayed the RVNAb production; BW006 co-operated with aluminum to enhance the immunogenicity of IRV; BW006 reduced the immunization shots of rabies vaccines; BW006 augmented the rabies vaccine with or without aluminum to induce effective protection of mice against rabies virus. The results indicate that BW006 has the potential as rabies vaccine adjuvant. The immunization strategy against rabies might be adjusted to one in which the first shot is administered with rabies vaccine plus BW006, and the later shots with rabies vaccine containing both aluminum and BW006.
1.3 Immunogenicity of inactivated influenza vaccine enhanced by BW006
Influenza virus easily causes sustained pandemic and vaccine supply is insufficient to meed the needs of potential pandemic mediated by the frequent re-assortment between two different virus strains or subtype strains. To determine the enhancement of BW006 on inactivated influenza vaccine, we performed a series of experiments in mice. The results showed that: BW006 improved earlier production of high level antibody induced by low dose of H3N2 antigen and prolonged production of high level antibody induced by high dose of H3N2 antigen; BW006 reduced H3N2 antigen doses to 1/8th dose and enhanced recalled proliferation of mouse splenocytes of mice immunized with H3N2 antigen stimulated by different influenza subtype strain. Furthermore, we identified the enhancement effect of BW006 on the inactivated influenza spilit vaccine. Similarly, BW006 reduced the full vaccine dose to 1/10th dose and promoted IgG2a production in mouse serum. In conclusion, the superiority of BW006 as influenza vaccine adjuvant is to reduce vaccine dose, increase cross-reactivity to different subtype strain and induce Th1 response.
2 The influence of CpG ODN on the pathogenecity of influenza virus
Based on the production of large amounts of anti-infective materials by CpG ODN stimulated immune cells, we conducted the in vivo experiments to observe the influence of CpG ODN on the acute infection caused by influenza virus. Influenza virus FM1 stain, which is safety for human, was used to infect mice. Body weight, survival rate, lung pathology, the levels of XOD and IL-12 in BALF were used to evaluate the immune effect of CpG ODN 1826 (1826), a prototype of B type CpG ODN in mouse. We unexpectedly found that 1826 inoculated before the influenza virus attack provided no protection for infected mice. On the contrary, 1826 aggravated the interstitial pneumonia, accelerated the body weight loss and promoted the death of infected mice, accompanished with the improved activity of xanthine oxidase and the high level IL-12 production in bronchoalveolar lavage fluid. The results suggest that CpG ODN seems to have side effects on self-limited flu-like acute infection, and the possible reason may be due to the synergy of CpG ODN and virus to stimulate the over secretion of inflammatory cytokines which damage body itself. Consequently, immunostimulating agents such as CpG ODN should be used cautiously in patients suffering from acute viral infection because of their potential to augment viral pathogenecity.
3 The influence of CpG ODN on tumor growth
The complex pathogenesis of carcinoma is associated with the low cure rates and high recurrence rates of these kinds of diseases. Any single-target drugs are insufficient for the cancer therapy. Adherence properties of tumor cells have important effects on tumor growth, invasion, and metastasis, so inhibition of tumor adherence becomes a new way to cure cancer. To study the capability of CpG ODN on the inhibition of tumor adherence, B16 cells were selected as tumor cell models for in vitro and in vivo experiments.
3.1 The influence of CpG ODN on the tumor cell adherence in vitro
For the purpose of screening CpG ODN with the ability to inhibit tumor cell adherence, cell counting experiments were used. In the process, self-designed CpG ODN, named as BW001, outshined others because of its dose-dependent inhibitions of tumor cell adherence, spreading and growth in vitro. Furthermore, a panel of CpG ODN were synthesized based on the structure of BW001 and were tested for their capacity to inhibit tumor cell adherence. The result showed that more than 5 continuous guanines (G) and fully PS-modified backbone, but not CpG motif were the necessary structures for BW001’s activity to inhibit cell adherence. Moreover, the activity of BW001 could be blocked by polycations (including poly-L-lysine, poly-L-arginine and poly-L-ornithine) and affected by FITC labeling, and could not influenced by dextran sulfate and chlorochine. These results indicate that the activity of BW001 on the inhibition of tumor cell adherence displays specific structure-dependence and is associated with polyanion character, but has no relationships with scavenger receptor or TLR9. The reduced inhibiton of FITC-BW001 may be due to the effect of FITC molecular on the formation of BW001 polymers.
3.2 The influence of CpG ODN on the tumor cell adherence ex vivo
Tumor metastasis is a multistep process and dependeds in part on the interactions of tumor cells and extracellular matrix (ECM) or endothelial cells. To study the activity of BW001 on the inhibition of tumor metastasis, fibronetin and typeⅠcollagen were used to mimic ECM and human umbilical vein endothelial cells (HUVECs) were used to mimic angiogenesis. The results showed that BW001 could inhibit the tumor cell adherence on ECM or inhibit the conformation of ECM mimicked by fibronetin and typeⅠcollagen; BW001 could inhibit tumor cell adherence to HUVECs. The results indicate that BW001 may inhibit tumor metastasis through the inhibition of cell adherence on ECM or endothelial cells.
Adherence to endothelium of distant organs may be partially responsible for the preferential metastatic patterns associated with differetent tumor types. Melanoma cells typically form tumor metastasis primarily in the lung. To observe the influence of BW001 on the lung metastasis of B16 cells, fresh cryostat sections of lung tissue were used to mimic lung microenviroment. The results showed that BW001 could inhibit the B16 cell adherence on lung tissue, incidating that BW001 may reduce the metastasis of tumor by the inhibition of tumor cell adherence on distant organs.
3.3 The influence of BW001 on the tumorigenicity of B16 cell in mice
To study the effect of BW001 on the inhibition of tumor growth and metastasis in vivo, we established three kinds of tumor models in mice with intraperitoneal, subcutaneous or intravenous injection of B16 cells mixed with or without BW001. We found that the BW001 could significantly decrease the tumor colony formations in peritoneal cavity and prolong the survival of tumor-bearing mice, delay the growth of subcutaneous tumor and inhibit the lung disseminateion of B16 cells via tail vein injection. The activity of BW001 displays sequence-dependence and structure-dependence: CG reversed control for BW001 failed to prolong the survival of tumor-bearing mice as compared with solvent did, indicating sequence-specific is a necessary condition for BW001’s activity. Moreover, the suppressing effect was weakened when polyG tail was removed or fully PS-modified backbone was changed to partially PS-modified backbone. Further study showed that the tumor inhibition activity of BW001 in these tumor models was induced by the direct interaction of BW001 and B16 cells and potential activation of immune system stimulated by BW001 may also participate in anti-tumor effects in peritoneal tumor model.
Based on all these results, we conclude that:
1 self-designed CpG ODN (BW006) may be a potential adjuvant for rabies vaccine and influenz vaccine.
2 Because of their potential to augment viral pathogenecity, immunostimulating agents such as CpG ODN should be used cautiously in patients suffering from acute viral infection.
3 Self-designed CpG ODN (BW001) may be developed into novel anti-neoplastic medication with the ability of tumor cell inhibition.
引文
1. Akuta T, Zaki MH, Yoshitake J, Okamoto T, Akaike T. Nitrative stress through formation of 8-nitroguanosine: insights into microbial pathogenesis. Nitric Oxide. 2006 Mar;14(2):101-8. Epub 2005 Nov 23.
2. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994 Feb;4(1):35-45.
3. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.
4. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol. 2003 Aug;77(16):8948-56.
5. Asselah T, Boyer N, Ripault MP, Martinot M, Marcellin P. Management of hepatitis C infections. Minerva Gastroenterol Dietol. 2007 Mar;53(1):9-23.
6. Auf G, Chen L, Fornes P, Le Clanche C, Delattre JY, Carpentier AF. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett. 2002; 327(3): 189-92.
7. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001; 167(9):4878-86
8. Banerji A, Chakraborti J, Mitra A, Chatterjee A. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol. 2005;24(1):3-17.
9. Bao M, Zhang Y, Wan M, Dai L, Hu X, Wu X, Wang L, Deng P, Wang J, Chen J, Liu Y, Yu Y, Wang L. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol. 2006 Feb-Mar;118(2-3):180-7. Epub 2005 Nov 17
10. Barrett B. Rabies Heads Fatal Disease List Again. Veterinary Newsletter 2006;4(3):7.
11. Becker Y. A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications. Virus Genes. 2005; 30(1): 127-31
12. Benísek Z, Süli J, Eliás D, Lenhardt L, Ondrejková A, Ondrejka R, Svrcek S, Bajová V Experimental squalene adjuvant. II. Harmlessness and local reactogenity. Vaccine. 2004 Sep 3;22(25-26):3470-4.
13. Berlin BS. Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination. Am J Public Health 1990;80(4):476–478.
14. Blackwell SE, Krieg AM. CpG-A-Induced Monocyte IFN-γ Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α. J Immunol. 2003; 170: 4061-4068.
15. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008 Mar 18.
16. Cabasso VJ, Dobkin MB, Roby RE, Hammar AH. Antibody response to a human diploid cellrabies vaccine. Appl Microbiol 1974;27(3):553-561.
17. Castignolles N, Morgeaux S, Gontier-Jallet C, Samain D, Betbeder D, Perrin P. A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. Vaccine. 1996 Oct;14(14):1353-60.
18. Chadha KC, Dembinski WE, Dunn CB, Aradi J, Bardos TJ, Dunn JA, Ambrus JL Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly I:poly C on the alpha, beta and gamma interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004 Dec;64(3):171-7.
19. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci. 1893;105:487–511.
20. Cong Z, Wan M, Wu X, Wang L, Hu X, Yang F, Bao M, Zhang X, Chen J, Wang L, Yu Y. A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2007 Oct;51(1):26-34. Epub 2007 Jun 30
21. Costa L.T., Kerkmann M., Hartmann G., Endres S., Bisch P.M., Heckl W.M., Thalhammer S. Structural studies of oligonucleotides containing G-quadruplex motifs using AFM. Biochem. Biophys. Res. Commun. 2004;313:1065–72.
22. Cox RJ, Hovden AO, Brokstad KA, Szyszko E, Madhun AS, Haaheim LR. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 2006 Nov 10;24(44-46):6585-7. Epub 2006 Jun 5.
23. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007 Mar 9;128(5):853-64.
24. Dapi? V, Abdomerovi? V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res. 2003 Apr 15;31(8):2097-107.
25. Dapi? V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry. 2002 Mar 19;41(11):3676-85.
26. Davis HL,Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160(2):870-876.
27. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007 Dec 21;26(1):119-27. Epub 2007 Nov 12.
28. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 2005 Jan 4;6:1.
29. Du YC, Lin P, Zhang J, Lu YR, Ning QZ, Wang Q. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens. 2006 May;67(5):368-76.
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991-8.
31. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia. 2006 Nov 1;54(6):526-35.
32. Epstein SL, Stack A, Misplon JA, Lo CY, Mostowski H, Bennink J, Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol. 2000 Jan;12(1):91-101.
33. Ferko B, Stasakova J, Romanova J, Kittel C, Sereinig S, Katinger H, Egorov A. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol. 2004 Dec;78(23):13037-45.
34. Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun. 2005 Aug;73(8):4948-54.
35. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 1999 May 4;17(18):2237-44.
36. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15;105(2):489-95. Epub 2004 Sep 9.
37. Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol. 1999 Apr 1;162(7):4163-70.
38. Furukawa Y, Bangham CRM, Taylor GP, Weber JN, Osame M. Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Clin Exp Immunol 2000;120(2):307-316.
39. Geeraedts F, Bungener L, Pool J, Veer WT, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza and Other Respiratory Viruses. 2008:1750-2659.
40. Glück R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther. 2004 Jul;4(7):1139-45.
41. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000 Nov;68(5):556-67.
42. Gotto J, Dusheiko GM. Hepatitis C and treatment with pegylated interferon and ribavirin. Int J Biochem Cell Biol. 2004 Oct;36(10):1874-7.
43. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12 and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001; 69(3): 1643-9.
44. Grandjenette C, Kennel A, Faure GC, Béné MC, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica. 2007 Sep;92(9):1279-81.
45. Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH. Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol. 2004 Dec 15;173(12):7269-76.
46. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 2002;32(9): 2617-2622.
47. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007 Jul;5(7):505-17.
48. Guzylack-Piriou L, Balmelli C, McCullough KC, Summerfield A. Type-A CpG oligonucleotidesactivate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12. Immunology. 2004 May;112(1):28-37.
49. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004 Mar;10(3):290-3.
50. Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, Herschler GB, Glezen WP. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16;25(20):4038-45. Epub 2007 Mar 12.
51. Harris TH, Mansfield JM, Paulnock DM. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect Immun. 2007 May;75(5):2366-73. Epub 2007 Mar 5.
52. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.
53. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM. Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo. J Immunol. 2000; 164: 1617–1624
54. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999; 96(16): 9305-9310.
55. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173(7):4479–4491.
56. He H, Crippen TL, Farnell MB, Kogut MH. Identification of CpG oligodeoxynucleotide motifs that stimulate nitric oxide and cytokine production in avian macrophage and peripheral blood mononuclear cells. Dev Comp Immunol. 2003 Jun-Jul;27(6-7):621-7.
57. He H, Genovese KJ, Lowry VK, Nisbet DJ, Kogut MH. Response of nitric oxide production to CpG oligodeoxynucleotides in turkey and chicken peripheral blood monocytes. FEMS Immunol Med Microbiol. 2006 Oct;48(1):99-106.
58. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. 2002; 169(7): 3892-9.
59. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004 Feb;10(2):187-92. Epub 2004 Jan 25.
60. Hemachudha T, Sunsaneewitayakul B, Mitrabhakdi E, Suankratay C, Laothamathas J, Wacharapluesadee S, et al. Paralytic complications following intravenous rabies immuneglobulin treatment in a patient with furious rabies. Int J Infect Dis 2003;7(1):76-77.
61. Hesse AK, D?rger M, Kupatt C, Krombach F. Proinflammatory role of inducible nitric oxide synthase in acute hyperoxic lung injury. Respir Res. 2004 Sep 15;5:11.
62. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003 Sep 1;63(17):5198-202.
63. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 Jan;11(1):91-100.
64. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005 Apr 21;434(7036):1035-40.
65. Hu J, Asbury TM, Achuthan S, Li C, Bertram R, Quine JR, Fu R, Cross TA. Backbone Structure of the Amantadine-blocked Trans-membrane Domain M2 Proton Channel from Influenza A Virus. Biophys J. 2007 Mar 23;(Epub ahead of print).
66. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986 Jul 25;233(4762):467-70.
67. Ikeda M, Minari J, Shimada N, Numata M, Sakurai K, Shinkai S. Complex formation between cationic beta-1,3-glucan and hetero-sequence oligodeoxynucleotide and its delivery into macrophage-like cells to induce cytokine secretion. Org Biomol Chem. 2007 Jul 21;5(14):2219-24. Epub 2007 Jun 7.
68. Ikeda M, Minari J, Shimada N, Numata M, Sakurai K, Shinkai S. Complex formation between cationic beta-1,3-glucan and hetero-sequence oligodeoxynucleotide and its delivery into macrophage-like cells to induce cytokine secretion. Org Biomol Chem. 2007 Jul 21;5(14):2219-24. Epub 2007 Jun 7.
69. Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology. 1999 Jul-Aug;46(28):2648-53.
70. Infante-Duarte C, Kamradt T. Thl/Th2 balance in infection. Springer Semin Immunopathol 1999;21(3):317-338.
71. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005 Jun;79(11):7269-72.
72. Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol. 2005; 174(2): 777-82
73. Ito S, Ishii KJ, Ihata A, Klinman DM. Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes. Infect Immun. 2005a Jun;73(6):3803-5.
74. Ito S, Pedras-Vasconcelos J, Klinman DM. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun. 2005b Sep;73(9):6154-6.
75. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005 Feb 15;11(4):1490-9.
76. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a J Immunol 2007; 178(4): 2415 – 2420.
77. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004 May 1;172(9):5598-605.
78. Jiang X, Zeng HS, Guo Y, Zhou ZB, Tang BS, Li FK. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl). 2004 Dec;117(12):1825-9.
79. Józefowski S, Sulahian TH, Arredouani M, Kobzik L. Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides. J Leukoc Biol. 2006 Oct;80(4):870-9. Epub2006 Aug 1.
80. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol. 2001 Feb 15;166(4):2291-5.
81. Kang IC, Kim DS, Jang Y, Chung KH. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem Biophys Res Commun. 2000 Aug 18;275(1):169-73.
82. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001; 167(9): 5247-53.
83. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G. Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. J Immunol. 2003; 170(9): 4465-74
84. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G. Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. J Immunol. 2003; 170(9): 4465-74.
85. Kerkmann M., Costa L.T., Richter C., Rothenfusser S., Battiany J., Hornung V., Johnson J., Englert S., Ketterer T., Heckl W., et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-{alpha} induction by cpg-a in plasmacytoid dendritic cells. J. Biol. Chem. 2005;280:8086–93.
86. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006 Jan;12(1):9-14.
87. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985;161(1):1-17.
88. Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology 1979 ;38(4):687-695.
89. Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs. 2005 Feb;14(2):135-61.
90. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006 May 1;66(9):4662-71.
91. Kraft AR, Krux F, Schimmer S, Ohlen C, Greenberg PD, Dittmer U. CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood. 2007 Apr 1;109(7):2982-4.
92. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. Nature. 1995 Apr 6;374(6522):546-9
93. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007a;4(3):289 - 294.
94. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May;117(5):1184-94.
95. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.
96. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7.
97. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis. 2005;22(1):11-24.
98. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol. 2003; 170(7): 3468-77.
99. Kuramoto Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release. 2006 Oct 10;115(2):226-33. Epub 2006 Aug 12.
100. Lacovara J, Cramer EB, Quigley JP. Fibronectin enhancement of directed migration of B 16 melanoma cells. Cancer Res. 1984 Apr;44(4):1657-63
101. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15;179(4):2493-500.
102. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg. 2001;18(4):260-73.
103. Lin HX, Gontier C, Saron MF, Perrin P. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Arch Virol. 1993;131(3-4):307-19.
104. Lin HX, Perrin P. Influence of aluminum adjuvant to experimental rabies vaccine. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1999;13(2):133-135.
105. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004 Oct;82(5):497-505.
106. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG directly induces T bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4(7):687–693.
107. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003; 171(8): 3941-6.
108. Luganini A, Caposio P, Landolfo S, Gribaudo G . Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry . Antimicrob Agents Chemother. 2008 Mar;52(3):1111-20.
109. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis. 2006 Jan;12(1):66-72.
110. Mao QG, Luo KX, Zhang MX, Liu D, Hou JL. Generation of neutralizing anti-interferon antibodies and factors influencing their production in chronic hepatitis B patients receiving recombinant interferon-alpha treatment Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(12): 1319-22.
111. Markine-Goriaynoff D, van der Logt JT, Truyens C, Nguyen TD, Heessen FW, Bigaignon G,et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000;12(2):223-230.
112. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003; 73(6): 781-92.
113. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xeno-cannibalism as an exacerbation of self-cannibalism: a possible fruitful survival strategy for cancer cells. Curr Pharm Des. 2008;14(3):245-52.
114. McCarthy JB, Furcht LT. Laminin and fibronectin promote the haptotactic migration of B16 mousemelanoma cells in vitro. J Cell Biol. 1984 Apr;98(4):1474-80.
115. McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Lev DC, Bar-Eli M. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15;9(17):6560-6.
116. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65.
117. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
118. Miranda M, Ligas C, Amicarelli F, D'Alessandro E, Brisdelli F, Zarivi O, Poma A. Sister chromatid exchange (SCE) rates in human melanoma cells as an index of mutagenesis. Mutagenesis. 1997 Jul;12(4):233-6.
119. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol. 2006 Oct;126(10):2272-80. Epub 2006 Jun 1.
120. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999 Oct;5(10):1157-63.
121. Netland PA, Zetter BR.Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. J Cell Biol. 1985 Sep;101(3):720-4.
122. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 2006;24(1):19-28.
123. No Author. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int. 2006 Feb;15(81):21-30.
124. Nonnenmacher C, Dalpke A, Zimmermann S, Flores-De-Jacoby L, Mutters R, Heeg K. DNA from periodontopathogenic bacteria is immunostimulatory for mouse and human immune cells. Infect Immun. 2003 Feb;71(2):850-6.
125. Novakovi? S, Stegel V, Kopitar A, Ihan A, Novakovi? BJ. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine. 2007 Nov 28;25(49):8241-56. Epub 2007 Oct 17.
126. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4240-3.
127. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science. 1989 May 26;244(4907):974-6.
128. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007 Oct;6(5):699-710.
129. oir B, Bouchard B, Morandini R, Del Marmol V, Deraemaecker R, Garcia-Borron JC, Ghanem G. Immunoreactive alpha-melanotropin as an autocrine effector in human melanoma cells. Eur J Biochem. 1997 Mar 15;244(3):923-30.
130. Olbrich AR, Schimmer S, Dittmer U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol. 2003 Oct;77(19):10658-62.
131. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U. Effectivepostexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol. 2002 Nov;76(22):11397-404.
132. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol. 2002 Nov;76(22):11397-404.
133. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005 Apr;11(4 Suppl):S63-8.
134. Patel PS, Yang S, Li A, Varney ML, Singh RK. Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1alpha in human malignant melanoma cells. J Cancer Res Clin Oncol. 2002 Sep;128(9):461-8. Epub 2002 Aug 21.
135. Pedras-Vasconcelos JA, Goucher D, Puig M, Tonelli LH, Wang V, Ito S, Verthelyi D. CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. J Immunol. 2006 Apr 15;176(8):4940-9.
136. Peng CG, Damha MJ. G-quadruplex induced stabilization by 2'-deoxy-2'-fluoro-D-arabinonucleic acids (2'F-ANA). Nucleic Acids Res. 2007;35(15):4977-88. Epub 2007 Jul 17.
137. Peng HH, Hodgson L, Henderson AJ, Dong C . Involvement of phospholipase C signaling in melanoma cell-induced endothelial junction disassembly. Front Biosci. 2005 May 1;10:1597-606.
138. Pichierri F, Sarai A. Properties of phosphorothioate DNA analogs. An ab initio study of prototype model linkages derived from dimethyl-phosphate anion. J MOL STRUC-THEOCHEM 460 (1-3): 103-116 FEB 26 1999.
139. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.
140. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005 Apr;11(4 Suppl):S5-11.
141. Puig M, Grajkowski A, Boczkowska M, Ausín C, Beaucage SL, Verthelyi D. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleic Acids Res. 2006;34(22):6488-95. Epub 2006 Nov 27
142. Qi H, Lin CP, Fu X, Wood LM, Liu AA, Tsai YC, Chen Y, Barbieri CM, Pilch DS, Liu LF. G-quadruplexes induce apoptosis in tumor cells. Cancer Res. 2006 Dec 15;66(24):11808-16.
143. Rajsbaum R, Stoye JP, O'Garra A. Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur J Immunol. 2008 Mar;38(3):619-30.
144. Reed LJ, Muench H. A simple method of estimating fifity percent end-points. Am J Hyg 1938;27(3):493-497.
145. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional Expression of TLR9 is Associated to the Metastatic Potential of Human Lung Cancer Cell: Functional Active Role of TLR9 on Tumor Metastasis. Cancer Biol Ther. 2007 Aug 3;6(11).
146. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine. 2001 Oct 12;20(1-2):158-63.
147. Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005 Aug 1;175(3):1619-27.
148. Rooijakkers E, Groen J, Uittenbogarrd J, van Herwijnen J, Osterhaus A. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Dev Biol Stand 1996;86:137-145.
149. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004 Sep;34(9):2541-50.
150. Saccà B, Lacroix L, Mergny JL. The effect of chemical modifications on the thermal stability of different G-quadruplex-forming oligonucleotides. Nucleic Acids Res. 2005 Feb 24;33(4):1182-92. Print 2005.
151. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A, Fung-Leung WP, Colonna M, Karlsson L. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol. 2006 Mar 27;172(7):1057-68.
152. Schwartz TR, Vasta CA, Bauer TL, Parekh-Olmedo H, Kmiec EB. G-Rich Oligonucleotides Alter Cell Cycle Progression and Induce Apoptosis Specifically in OE19 Esophageal Tumor Cells. Oligonucleotides. 2008 Spring;18(1):51-63.
153. Schwartz TR, Vasta CA, Bauer TL, Parekh-Olmedo H, Kmiec EB. G-Rich Oligonucleotides Alter Cell Cycle Progression and Induce Apoptosis Specifically in OE19 Esophageal Tumor Cells. Oligonucleotides. 2008 Spring;18(1):51-63.
154. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005 Mar 15;65(6):2412-21.
155. Shayam C, Duggal AK, Kamble U, Agarwal AK. Post-exposure Prophylaxis for Rabies. JIACM 2006; 7(1): 39-46.
156. Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):155-64.
157. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1.J Cell Biol. 2008 Mar 24;180(6):1277-89.
158. Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005 Apr 15;174(8):4579-83.
159. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004 Oct 18;23(48):8017-23.
160. Simani S, Nejad PM, Amirkhani A, Feizabadi MM, Elahi E, Fayaz A. Comparison of three serological tests for titration of rabies antibodies in immunized individuals. Arch Iran Med 1999;2(3):125-127.
161. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46.
162. Süli J, Benísek Z, Eliás D, Svrcek S, Ondrejková A, Ondrejka R, Bajová V. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Vaccine. 2004 Sep 3;22(25-26):3464-9.
163. Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol. 2005; 75(3): 391-8
164. Suzuki K, Suda T, Naito T, Ide K, Chida K, Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med. 2005 Apr 1;171(7):707-13. Epub 2005 Jan 7.
165. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005 Aug;58(4):195-207.
166. Tanaka K, Noda S, Sawamura S, Kabir AM, Koga Y. Nitric oxide targets bronchiolar epithelial cells in murine cytomegalovirus-associated disease in lungs that are free of the virus. Arch Virol. 2001 Aug;146(8):1499-515.
167. Tang XC, Luo M, Zhang SY, Fooks AR, Hu RL, Tu CC. Pivotal role of dogs in rabies transmission,China. Emerg Infect Dis 2005;11(12):1970-1972.
168. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006 Oct;16(5):405-11.
169. Tipping PG. Toll-like receptors: the interface between innate and adaptive immunity. J Am Soc Nephrol. 2006 Jul;17(7):1769-71. Epub 2006 Jun 14.
170. Utaisincharoen P, Kespichayawattana W, Anuntagool N, Chaisuriya P, Pichyangkul S, Krieg AM, Sirisinha S. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol. 2003 Apr;132(1):70-5.
171. Uzunkoy A, Bolukbas C, Horoz M, Bolukbas FF, Kocyigit A. The optimal starting time of postoperative intraperitoneal mitomycin-C therapy with preserved intestinal wound healing. BMC Cancer. 2005 Mar 31;5:31.
172. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005 Jan 11;23(8):1029-36.
173. van Rijswijk RE, Hoekman K, Burger CW, Verheijen RH, Vermorken JB. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol. 1997 Dec;8(12):1235-41.
174. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002;100(3):813-822.
175. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.
176. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.
177. von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog. 2006 Oct;45(10):786-94.
178. Wang JP, Hayashi T, Datta SK, Kornbluth RS, Raz E, Guiney DG. CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):303-10.
179. Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. Hemagglutinin (HA)proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec;80(23):11628-37. Epub 2006 Sep 20.
180. Wei J, Xiong Y. Inhibitory effect of recombinant fibronectin polypeptide CH50 on invasion and metastasis of melanoma B16 cells. J Huazhong Univ Sci Technolog Med Sci. 2007 Feb;27(1):17-9.
181. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol. 2000 Oct 15;165(8):4537-43.
182. WHO Expert Consultation on Rabies. First report. World Health Organization, Geneva, 1992 (WHO Technical Report Series; 931).
183. WHO. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Tech Rep Ser. No. 840 (Annex 5) 1994.
184. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004 Aug;72(8):4494-502.
185. Wu C.C.N., Lee J., Raz E., Corr M., Carson D. Necessity of oligonucleotide aggregation for Toll-like receptor 9 activation. J. Biol. Chem. 2004;279:33071–8.
186. Wunderli PS, Dreesen DW, Miller TJ, Baer GM. Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice. Am J Vet Res 2003;64(4): 491-498.
187. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res. 2003 Oct 3;93(7):664-73. Epub 2003 Sep 4.
188. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 1998;160:5898–5906.
189. Zaki MH, Akuta T, Akaike T. Nitric oxide-induced nitrative stress involved in microbial pathogenesis. J Pharmacol Sci. 2005 Jun;98(2):117-29. Epub 2005 Jun 4.
190. Zhu D, Cheng CF, Pauli BU. Blocking of lung endothelial cell adhesion molecule-1 (Lu-ECAM-1) inhibits murine melanoma lung metastasis. J Clin Invest. 1992 Jun;89(6):1718-24.
191. Zimmermann S, Egeter O, Hausmann S, Lipford GB, R?cken M, Wagner H and et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998;160(8):3627-3630.
192. Zimmermann, S., O. Egeter, S. Hausmann, G. B. Lipford, M. Rocken, H.Wagner, and K. Heeg. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. 1998.J. Immunol.160:3627–30.
193. 王学菊,王智博,卫红飞,吴秀丽,王莉,于永利,王丽颖. C 型 CpG 单链寡核苷酸对肿瘤疫苗抑瘤效果的增强作用 [J]. 细胞与分子免疫学杂志,2007, 23(4):338-340,342.
2. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994 Feb;4(1):35-45.
3. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.
4. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol. 2003 Aug;77(16):8948-56.
5. Asselah T, Boyer N, Ripault MP, Martinot M, Marcellin P. Management of hepatitis C infections. Minerva Gastroenterol Dietol. 2007 Mar;53(1):9-23.
6. Auf G, Chen L, Fornes P, Le Clanche C, Delattre JY, Carpentier AF. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett. 2002; 327(3): 189-92.
7. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001; 167(9):4878-86
8. Banerji A, Chakraborti J, Mitra A, Chatterjee A. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol. 2005;24(1):3-17.
9. Bao M, Zhang Y, Wan M, Dai L, Hu X, Wu X, Wang L, Deng P, Wang J, Chen J, Liu Y, Yu Y, Wang L. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol. 2006 Feb-Mar;118(2-3):180-7. Epub 2005 Nov 17
10. Barrett B. Rabies Heads Fatal Disease List Again. Veterinary Newsletter 2006;4(3):7.
11. Becker Y. A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications. Virus Genes. 2005; 30(1): 127-31
12. Benísek Z, Süli J, Eliás D, Lenhardt L, Ondrejková A, Ondrejka R, Svrcek S, Bajová V Experimental squalene adjuvant. II. Harmlessness and local reactogenity. Vaccine. 2004 Sep 3;22(25-26):3470-4.
13. Berlin BS. Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination. Am J Public Health 1990;80(4):476–478.
14. Blackwell SE, Krieg AM. CpG-A-Induced Monocyte IFN-γ Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α. J Immunol. 2003; 170: 4061-4068.
15. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008 Mar 18.
16. Cabasso VJ, Dobkin MB, Roby RE, Hammar AH. Antibody response to a human diploid cellrabies vaccine. Appl Microbiol 1974;27(3):553-561.
17. Castignolles N, Morgeaux S, Gontier-Jallet C, Samain D, Betbeder D, Perrin P. A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. Vaccine. 1996 Oct;14(14):1353-60.
18. Chadha KC, Dembinski WE, Dunn CB, Aradi J, Bardos TJ, Dunn JA, Ambrus JL Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly I:poly C on the alpha, beta and gamma interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004 Dec;64(3):171-7.
19. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci. 1893;105:487–511.
20. Cong Z, Wan M, Wu X, Wang L, Hu X, Yang F, Bao M, Zhang X, Chen J, Wang L, Yu Y. A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2007 Oct;51(1):26-34. Epub 2007 Jun 30
21. Costa L.T., Kerkmann M., Hartmann G., Endres S., Bisch P.M., Heckl W.M., Thalhammer S. Structural studies of oligonucleotides containing G-quadruplex motifs using AFM. Biochem. Biophys. Res. Commun. 2004;313:1065–72.
22. Cox RJ, Hovden AO, Brokstad KA, Szyszko E, Madhun AS, Haaheim LR. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 2006 Nov 10;24(44-46):6585-7. Epub 2006 Jun 5.
23. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007 Mar 9;128(5):853-64.
24. Dapi? V, Abdomerovi? V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res. 2003 Apr 15;31(8):2097-107.
25. Dapi? V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry. 2002 Mar 19;41(11):3676-85.
26. Davis HL,Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160(2):870-876.
27. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007 Dec 21;26(1):119-27. Epub 2007 Nov 12.
28. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 2005 Jan 4;6:1.
29. Du YC, Lin P, Zhang J, Lu YR, Ning QZ, Wang Q. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens. 2006 May;67(5):368-76.
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991-8.
31. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia. 2006 Nov 1;54(6):526-35.
32. Epstein SL, Stack A, Misplon JA, Lo CY, Mostowski H, Bennink J, Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol. 2000 Jan;12(1):91-101.
33. Ferko B, Stasakova J, Romanova J, Kittel C, Sereinig S, Katinger H, Egorov A. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol. 2004 Dec;78(23):13037-45.
34. Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun. 2005 Aug;73(8):4948-54.
35. Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 1999 May 4;17(18):2237-44.
36. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15;105(2):489-95. Epub 2004 Sep 9.
37. Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol. 1999 Apr 1;162(7):4163-70.
38. Furukawa Y, Bangham CRM, Taylor GP, Weber JN, Osame M. Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Clin Exp Immunol 2000;120(2):307-316.
39. Geeraedts F, Bungener L, Pool J, Veer WT, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza and Other Respiratory Viruses. 2008:1750-2659.
40. Glück R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther. 2004 Jul;4(7):1139-45.
41. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000 Nov;68(5):556-67.
42. Gotto J, Dusheiko GM. Hepatitis C and treatment with pegylated interferon and ribavirin. Int J Biochem Cell Biol. 2004 Oct;36(10):1874-7.
43. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12 and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001; 69(3): 1643-9.
44. Grandjenette C, Kennel A, Faure GC, Béné MC, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica. 2007 Sep;92(9):1279-81.
45. Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH. Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol. 2004 Dec 15;173(12):7269-76.
46. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 2002;32(9): 2617-2622.
47. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007 Jul;5(7):505-17.
48. Guzylack-Piriou L, Balmelli C, McCullough KC, Summerfield A. Type-A CpG oligonucleotidesactivate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12. Immunology. 2004 May;112(1):28-37.
49. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004 Mar;10(3):290-3.
50. Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, Herschler GB, Glezen WP. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16;25(20):4038-45. Epub 2007 Mar 12.
51. Harris TH, Mansfield JM, Paulnock DM. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect Immun. 2007 May;75(5):2366-73. Epub 2007 Mar 5.
52. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.
53. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM. Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo. J Immunol. 2000; 164: 1617–1624
54. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999; 96(16): 9305-9310.
55. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004;173(7):4479–4491.
56. He H, Crippen TL, Farnell MB, Kogut MH. Identification of CpG oligodeoxynucleotide motifs that stimulate nitric oxide and cytokine production in avian macrophage and peripheral blood mononuclear cells. Dev Comp Immunol. 2003 Jun-Jul;27(6-7):621-7.
57. He H, Genovese KJ, Lowry VK, Nisbet DJ, Kogut MH. Response of nitric oxide production to CpG oligodeoxynucleotides in turkey and chicken peripheral blood monocytes. FEMS Immunol Med Microbiol. 2006 Oct;48(1):99-106.
58. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. 2002; 169(7): 3892-9.
59. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med. 2004 Feb;10(2):187-92. Epub 2004 Jan 25.
60. Hemachudha T, Sunsaneewitayakul B, Mitrabhakdi E, Suankratay C, Laothamathas J, Wacharapluesadee S, et al. Paralytic complications following intravenous rabies immuneglobulin treatment in a patient with furious rabies. Int J Infect Dis 2003;7(1):76-77.
61. Hesse AK, D?rger M, Kupatt C, Krombach F. Proinflammatory role of inducible nitric oxide synthase in acute hyperoxic lung injury. Respir Res. 2004 Sep 15;5:11.
62. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003 Sep 1;63(17):5198-202.
63. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 Jan;11(1):91-100.
64. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005 Apr 21;434(7036):1035-40.
65. Hu J, Asbury TM, Achuthan S, Li C, Bertram R, Quine JR, Fu R, Cross TA. Backbone Structure of the Amantadine-blocked Trans-membrane Domain M2 Proton Channel from Influenza A Virus. Biophys J. 2007 Mar 23;(Epub ahead of print).
66. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986 Jul 25;233(4762):467-70.
67. Ikeda M, Minari J, Shimada N, Numata M, Sakurai K, Shinkai S. Complex formation between cationic beta-1,3-glucan and hetero-sequence oligodeoxynucleotide and its delivery into macrophage-like cells to induce cytokine secretion. Org Biomol Chem. 2007 Jul 21;5(14):2219-24. Epub 2007 Jun 7.
68. Ikeda M, Minari J, Shimada N, Numata M, Sakurai K, Shinkai S. Complex formation between cationic beta-1,3-glucan and hetero-sequence oligodeoxynucleotide and its delivery into macrophage-like cells to induce cytokine secretion. Org Biomol Chem. 2007 Jul 21;5(14):2219-24. Epub 2007 Jun 7.
69. Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology. 1999 Jul-Aug;46(28):2648-53.
70. Infante-Duarte C, Kamradt T. Thl/Th2 balance in infection. Springer Semin Immunopathol 1999;21(3):317-338.
71. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005 Jun;79(11):7269-72.
72. Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol. 2005; 174(2): 777-82
73. Ito S, Ishii KJ, Ihata A, Klinman DM. Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes. Infect Immun. 2005a Jun;73(6):3803-5.
74. Ito S, Pedras-Vasconcelos J, Klinman DM. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun. 2005b Sep;73(9):6154-6.
75. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005 Feb 15;11(4):1490-9.
76. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a J Immunol 2007; 178(4): 2415 – 2420.
77. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004 May 1;172(9):5598-605.
78. Jiang X, Zeng HS, Guo Y, Zhou ZB, Tang BS, Li FK. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl). 2004 Dec;117(12):1825-9.
79. Józefowski S, Sulahian TH, Arredouani M, Kobzik L. Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides. J Leukoc Biol. 2006 Oct;80(4):870-9. Epub2006 Aug 1.
80. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol. 2001 Feb 15;166(4):2291-5.
81. Kang IC, Kim DS, Jang Y, Chung KH. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem Biophys Res Commun. 2000 Aug 18;275(1):169-73.
82. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001; 167(9): 5247-53.
83. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G. Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. J Immunol. 2003; 170(9): 4465-74
84. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G. Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells. J Immunol. 2003; 170(9): 4465-74.
85. Kerkmann M., Costa L.T., Richter C., Rothenfusser S., Battiany J., Hornung V., Johnson J., Englert S., Ketterer T., Heckl W., et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-{alpha} induction by cpg-a in plasmacytoid dendritic cells. J. Biol. Chem. 2005;280:8086–93.
86. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006 Jan;12(1):9-14.
87. Kipps TJ, Parham P, Punt J, Herzenberg LA. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985;161(1):1-17.
88. Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology 1979 ;38(4):687-695.
89. Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs. 2005 Feb;14(2):135-61.
90. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006 May 1;66(9):4662-71.
91. Kraft AR, Krux F, Schimmer S, Ohlen C, Greenberg PD, Dittmer U. CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood. 2007 Apr 1;109(7):2982-4.
92. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. Nature. 1995 Apr 6;374(6522):546-9
93. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007a;4(3):289 - 294.
94. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May;117(5):1184-94.
95. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.
96. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7.
97. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis. 2005;22(1):11-24.
98. Krug A, Rothenfusser S, Selinger S, Bock C, Kerkmann M, Battiany J, Sarris A, Giese T, Speiser D, Endres S, Hartmann G. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol. 2003; 170(7): 3468-77.
99. Kuramoto Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release. 2006 Oct 10;115(2):226-33. Epub 2006 Aug 12.
100. Lacovara J, Cramer EB, Quigley JP. Fibronectin enhancement of directed migration of B 16 melanoma cells. Cancer Res. 1984 Apr;44(4):1657-63
101. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15;179(4):2493-500.
102. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg. 2001;18(4):260-73.
103. Lin HX, Gontier C, Saron MF, Perrin P. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Arch Virol. 1993;131(3-4):307-19.
104. Lin HX, Perrin P. Influence of aluminum adjuvant to experimental rabies vaccine. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1999;13(2):133-135.
105. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004 Oct;82(5):497-505.
106. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG directly induces T bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4(7):687–693.
107. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003; 171(8): 3941-6.
108. Luganini A, Caposio P, Landolfo S, Gribaudo G . Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry . Antimicrob Agents Chemother. 2008 Mar;52(3):1111-20.
109. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis. 2006 Jan;12(1):66-72.
110. Mao QG, Luo KX, Zhang MX, Liu D, Hou JL. Generation of neutralizing anti-interferon antibodies and factors influencing their production in chronic hepatitis B patients receiving recombinant interferon-alpha treatment Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(12): 1319-22.
111. Markine-Goriaynoff D, van der Logt JT, Truyens C, Nguyen TD, Heessen FW, Bigaignon G,et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000;12(2):223-230.
112. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003; 73(6): 781-92.
113. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xeno-cannibalism as an exacerbation of self-cannibalism: a possible fruitful survival strategy for cancer cells. Curr Pharm Des. 2008;14(3):245-52.
114. McCarthy JB, Furcht LT. Laminin and fibronectin promote the haptotactic migration of B16 mousemelanoma cells in vitro. J Cell Biol. 1984 Apr;98(4):1474-80.
115. McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Lev DC, Bar-Eli M. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15;9(17):6560-6.
116. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65.
117. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14.
118. Miranda M, Ligas C, Amicarelli F, D'Alessandro E, Brisdelli F, Zarivi O, Poma A. Sister chromatid exchange (SCE) rates in human melanoma cells as an index of mutagenesis. Mutagenesis. 1997 Jul;12(4):233-6.
119. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol. 2006 Oct;126(10):2272-80. Epub 2006 Jun 1.
120. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999 Oct;5(10):1157-63.
121. Netland PA, Zetter BR.Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. J Cell Biol. 1985 Sep;101(3):720-4.
122. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 2006;24(1):19-28.
123. No Author. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int. 2006 Feb;15(81):21-30.
124. Nonnenmacher C, Dalpke A, Zimmermann S, Flores-De-Jacoby L, Mutters R, Heeg K. DNA from periodontopathogenic bacteria is immunostimulatory for mouse and human immune cells. Infect Immun. 2003 Feb;71(2):850-6.
125. Novakovi? S, Stegel V, Kopitar A, Ihan A, Novakovi? BJ. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine. 2007 Nov 28;25(49):8241-56. Epub 2007 Oct 17.
126. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4240-3.
127. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science. 1989 May 26;244(4907):974-6.
128. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007 Oct;6(5):699-710.
129. oir B, Bouchard B, Morandini R, Del Marmol V, Deraemaecker R, Garcia-Borron JC, Ghanem G. Immunoreactive alpha-melanotropin as an autocrine effector in human melanoma cells. Eur J Biochem. 1997 Mar 15;244(3):923-30.
130. Olbrich AR, Schimmer S, Dittmer U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol. 2003 Oct;77(19):10658-62.
131. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U. Effectivepostexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol. 2002 Nov;76(22):11397-404.
132. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol. 2002 Nov;76(22):11397-404.
133. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005 Apr;11(4 Suppl):S63-8.
134. Patel PS, Yang S, Li A, Varney ML, Singh RK. Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1alpha in human malignant melanoma cells. J Cancer Res Clin Oncol. 2002 Sep;128(9):461-8. Epub 2002 Aug 21.
135. Pedras-Vasconcelos JA, Goucher D, Puig M, Tonelli LH, Wang V, Ito S, Verthelyi D. CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. J Immunol. 2006 Apr 15;176(8):4940-9.
136. Peng CG, Damha MJ. G-quadruplex induced stabilization by 2'-deoxy-2'-fluoro-D-arabinonucleic acids (2'F-ANA). Nucleic Acids Res. 2007;35(15):4977-88. Epub 2007 Jul 17.
137. Peng HH, Hodgson L, Henderson AJ, Dong C . Involvement of phospholipase C signaling in melanoma cell-induced endothelial junction disassembly. Front Biosci. 2005 May 1;10:1597-606.
138. Pichierri F, Sarai A. Properties of phosphorothioate DNA analogs. An ab initio study of prototype model linkages derived from dimethyl-phosphate anion. J MOL STRUC-THEOCHEM 460 (1-3): 103-116 FEB 26 1999.
139. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.
140. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005 Apr;11(4 Suppl):S5-11.
141. Puig M, Grajkowski A, Boczkowska M, Ausín C, Beaucage SL, Verthelyi D. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleic Acids Res. 2006;34(22):6488-95. Epub 2006 Nov 27
142. Qi H, Lin CP, Fu X, Wood LM, Liu AA, Tsai YC, Chen Y, Barbieri CM, Pilch DS, Liu LF. G-quadruplexes induce apoptosis in tumor cells. Cancer Res. 2006 Dec 15;66(24):11808-16.
143. Rajsbaum R, Stoye JP, O'Garra A. Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur J Immunol. 2008 Mar;38(3):619-30.
144. Reed LJ, Muench H. A simple method of estimating fifity percent end-points. Am J Hyg 1938;27(3):493-497.
145. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional Expression of TLR9 is Associated to the Metastatic Potential of Human Lung Cancer Cell: Functional Active Role of TLR9 on Tumor Metastasis. Cancer Biol Ther. 2007 Aug 3;6(11).
146. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine. 2001 Oct 12;20(1-2):158-63.
147. Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005 Aug 1;175(3):1619-27.
148. Rooijakkers E, Groen J, Uittenbogarrd J, van Herwijnen J, Osterhaus A. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Dev Biol Stand 1996;86:137-145.
149. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004 Sep;34(9):2541-50.
150. Saccà B, Lacroix L, Mergny JL. The effect of chemical modifications on the thermal stability of different G-quadruplex-forming oligonucleotides. Nucleic Acids Res. 2005 Feb 24;33(4):1182-92. Print 2005.
151. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A, Fung-Leung WP, Colonna M, Karlsson L. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol. 2006 Mar 27;172(7):1057-68.
152. Schwartz TR, Vasta CA, Bauer TL, Parekh-Olmedo H, Kmiec EB. G-Rich Oligonucleotides Alter Cell Cycle Progression and Induce Apoptosis Specifically in OE19 Esophageal Tumor Cells. Oligonucleotides. 2008 Spring;18(1):51-63.
153. Schwartz TR, Vasta CA, Bauer TL, Parekh-Olmedo H, Kmiec EB. G-Rich Oligonucleotides Alter Cell Cycle Progression and Induce Apoptosis Specifically in OE19 Esophageal Tumor Cells. Oligonucleotides. 2008 Spring;18(1):51-63.
154. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005 Mar 15;65(6):2412-21.
155. Shayam C, Duggal AK, Kamble U, Agarwal AK. Post-exposure Prophylaxis for Rabies. JIACM 2006; 7(1): 39-46.
156. Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):155-64.
157. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1.J Cell Biol. 2008 Mar 24;180(6):1277-89.
158. Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005 Apr 15;174(8):4579-83.
159. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004 Oct 18;23(48):8017-23.
160. Simani S, Nejad PM, Amirkhani A, Feizabadi MM, Elahi E, Fayaz A. Comparison of three serological tests for titration of rabies antibodies in immunized individuals. Arch Iran Med 1999;2(3):125-127.
161. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46.
162. Süli J, Benísek Z, Eliás D, Svrcek S, Ondrejková A, Ondrejka R, Bajová V. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. Vaccine. 2004 Sep 3;22(25-26):3464-9.
163. Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol. 2005; 75(3): 391-8
164. Suzuki K, Suda T, Naito T, Ide K, Chida K, Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med. 2005 Apr 1;171(7):707-13. Epub 2005 Jan 7.
165. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005 Aug;58(4):195-207.
166. Tanaka K, Noda S, Sawamura S, Kabir AM, Koga Y. Nitric oxide targets bronchiolar epithelial cells in murine cytomegalovirus-associated disease in lungs that are free of the virus. Arch Virol. 2001 Aug;146(8):1499-515.
167. Tang XC, Luo M, Zhang SY, Fooks AR, Hu RL, Tu CC. Pivotal role of dogs in rabies transmission,China. Emerg Infect Dis 2005;11(12):1970-1972.
168. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006 Oct;16(5):405-11.
169. Tipping PG. Toll-like receptors: the interface between innate and adaptive immunity. J Am Soc Nephrol. 2006 Jul;17(7):1769-71. Epub 2006 Jun 14.
170. Utaisincharoen P, Kespichayawattana W, Anuntagool N, Chaisuriya P, Pichyangkul S, Krieg AM, Sirisinha S. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol. 2003 Apr;132(1):70-5.
171. Uzunkoy A, Bolukbas C, Horoz M, Bolukbas FF, Kocyigit A. The optimal starting time of postoperative intraperitoneal mitomycin-C therapy with preserved intestinal wound healing. BMC Cancer. 2005 Mar 31;5:31.
172. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005 Jan 11;23(8):1029-36.
173. van Rijswijk RE, Hoekman K, Burger CW, Verheijen RH, Vermorken JB. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol. 1997 Dec;8(12):1235-41.
174. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, Berneman Z, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002;100(3):813-822.
175. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.
176. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.
177. von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog. 2006 Oct;45(10):786-94.
178. Wang JP, Hayashi T, Datta SK, Kornbluth RS, Raz E, Guiney DG. CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages. FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):303-10.
179. Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. Hemagglutinin (HA)proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec;80(23):11628-37. Epub 2006 Sep 20.
180. Wei J, Xiong Y. Inhibitory effect of recombinant fibronectin polypeptide CH50 on invasion and metastasis of melanoma B16 cells. J Huazhong Univ Sci Technolog Med Sci. 2007 Feb;27(1):17-9.
181. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol. 2000 Oct 15;165(8):4537-43.
182. WHO Expert Consultation on Rabies. First report. World Health Organization, Geneva, 1992 (WHO Technical Report Series; 931).
183. WHO. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Tech Rep Ser. No. 840 (Annex 5) 1994.
184. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004 Aug;72(8):4494-502.
185. Wu C.C.N., Lee J., Raz E., Corr M., Carson D. Necessity of oligonucleotide aggregation for Toll-like receptor 9 activation. J. Biol. Chem. 2004;279:33071–8.
186. Wunderli PS, Dreesen DW, Miller TJ, Baer GM. Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice. Am J Vet Res 2003;64(4): 491-498.
187. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res. 2003 Oct 3;93(7):664-73. Epub 2003 Sep 4.
188. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 1998;160:5898–5906.
189. Zaki MH, Akuta T, Akaike T. Nitric oxide-induced nitrative stress involved in microbial pathogenesis. J Pharmacol Sci. 2005 Jun;98(2):117-29. Epub 2005 Jun 4.
190. Zhu D, Cheng CF, Pauli BU. Blocking of lung endothelial cell adhesion molecule-1 (Lu-ECAM-1) inhibits murine melanoma lung metastasis. J Clin Invest. 1992 Jun;89(6):1718-24.
191. Zimmermann S, Egeter O, Hausmann S, Lipford GB, R?cken M, Wagner H and et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998;160(8):3627-3630.
192. Zimmermann, S., O. Egeter, S. Hausmann, G. B. Lipford, M. Rocken, H.Wagner, and K. Heeg. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. 1998.J. Immunol.160:3627–30.
193. 王学菊,王智博,卫红飞,吴秀丽,王莉,于永利,王丽颖. C 型 CpG 单链寡核苷酸对肿瘤疫苗抑瘤效果的增强作用 [J]. 细胞与分子免疫学杂志,2007, 23(4):338-340,342.